Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
relatlimab + nivolumab + ipilimumab + tumor-infiltrating lymphocytes
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cell Therapies
- Administration
- Intravenous
01
Overview
This combination immunotherapy regimen is being investigated in a Phase 1/2 clinical trial for the treatment of advanced ovarian, fallopian tube, and primary peritoneal cancers. The therapy consists of autologous tumor-infiltrating lymphocytes (TILs) administered following lymphodepleting chemotherapy, combined with three immune checkpoint inhibitors: relatlimab, nivolumab, and ipilimumab. Relatlimab is a monoclonal antibody that targets Lymphocyte Activation Gene-3 (LAG-3), an inhibitory receptor often expressed on T-cells that limits their anti-tumor activity. Nivolumab and ipilimumab target the PD-1 and CTLA-4 pathways, respectively. By blocking these three distinct immune checkpoints, the regimen aims to prevent T-cell exhaustion and enhance the efficacy of the infused TILs within the immunosuppressive tumor microenvironment of gynecological malignancies.
- Brand names
- OpdualagOpdivoYervoy
- Other names
- TIL therapy + relatlimab + nivolumab + ipilimumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on relatlimab + nivolumab + ipilimumab + tumor-infiltrating lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on relatlimab + nivolumab + ipilimumab + tumor-infiltrating lymphocytes.